Ningshao Xia

Chongqing University — China

Medicine · Health Sciences

82h-index30.1kcitations979works3.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hepatitis B Virus Studies(180), Viral gastroenteritis research and epidemiology(169), Hepatitis Viruses Studies and Epidemiology(154), Immunotherapy and Immune Responses(122), Monoclonal and Polyclonal Antibodies Research(114)

Publications975 total

Long-term protection from naturally acquired immunity against hepatitis E virus reinfection
Nature Communications·2025Open Access
Immunopersistence of one or two doses of an Escherichia coli produced bivalent HPV vaccine
npj Vaccines·2025Open Access
A broadly neutralizing antibody confers cross-genus protection against alphaherpesviruses by inhibiting gB-mediated membrane fusion
Nature Communications·2025· 2 citedOpen Access
Airborne transmission-mediated delivery of a live-attenuated influenza virus vector-based intranasal COVID-19 vaccine protects Syrian hamsters against SARS-CoV-2 challenge
npj Vaccines·2025Open Access
Engineering a multivalent antibody nanoparticle to overcome SARS-CoV-2 Omicron immune evasion
PLoS Pathogens·2025Open Access
Comparison of efficacy, safety, immune response of dNS1 LAIV and cold-adapted LAIV in a mouse model
npj Vaccines·2025Open Access
Supplementary Table S4 from Preliminary Cost-effectiveness and Cost-utility of Nasopharyngeal Carcinoma Screening with the Novel Biomarker Anti-BNLF2b Total Antibody
2025Open Access
Supplementary Figure S3 from Preliminary Cost-effectiveness and Cost-utility of Nasopharyngeal Carcinoma Screening with the Novel Biomarker Anti-BNLF2b Total Antibody
2025Open Access
Supplementary Figure S2 from Preliminary Cost-effectiveness and Cost-utility of Nasopharyngeal Carcinoma Screening with the Novel Biomarker Anti-BNLF2b Total Antibody
2025Open Access
Supplementary Table S5 from Preliminary Cost-effectiveness and Cost-utility of Nasopharyngeal Carcinoma Screening with the Novel Biomarker Anti-BNLF2b Total Antibody
2025Open Access
Supplementary Table S2 from Preliminary Cost-effectiveness and Cost-utility of Nasopharyngeal Carcinoma Screening with the Novel Biomarker Anti-BNLF2b Total Antibody
2025Open Access
Supplementary Figure S1 from Preliminary Cost-effectiveness and Cost-utility of Nasopharyngeal Carcinoma Screening with the Novel Biomarker Anti-BNLF2b Total Antibody
2025Open Access
Supplementary Table S3 from Preliminary Cost-effectiveness and Cost-utility of Nasopharyngeal Carcinoma Screening with the Novel Biomarker Anti-BNLF2b Total Antibody
2025Open Access
Supplementary Table S1 from Preliminary Cost-effectiveness and Cost-utility of Nasopharyngeal Carcinoma Screening with the Novel Biomarker Anti-BNLF2b Total Antibody
2025Open Access
Antibody‒drug conjugates with DHODH inhibitor as novel payload class for cancer and SARS-CoV-2 infection therapies
Acta Pharmaceutica Sinica B·2025Open Access
Engineered virus-hunter vaccine overcomes HBV immune tolerance
Gut·2025Open Access
An integrated centrifugal microfluidic chip for automated IGRA detection of tuberculosis
Sensors and Actuators B Chemical·2025· 1 cited
Symptom cluster in patients with resected pancreatic cancer during adjuvant chemotherapy: A cross-sectional study
Asia-Pacific Journal of Oncology Nursing·2025Open Access
An engineered VSV-vectored rabies vaccine with an RABV-G-L71S mutation
iScience·2025Open Access
Montanide ISA-51: a promising adjuvant in cancer vaccine immunotherapy
Expert Review of Vaccines·2025· 1 citedOpen Access
page 1 of 49Next →

Frequent Co-authors

Jun Zhang(24), Shengxiang Ge(17), Quan Yuan(13), Tianying Zhang(9), Ting Wu(8), Yingying Su(7), Shaowei Li(7), Mun‐Hon Ng(6), Yixin Chen(6), Tingdong Li(5), Fengcai Zhu(5), Shoujie Huang(5), Pei‐Jer Chen(5), Congming Hong(4), Yingxia Liu(4), Zizheng Zheng(4), Han-Min Jiang(4), Yuemei Hu(4), J. Wai‐Kuo Shih(4), Honglin Chen(4)